Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Environmental Links to Breast Cancer

July 1, 2001
Publication
Article
OncologyONCOLOGY Vol 15 No 7
Volume 15
Issue 7

Two senators have introduced legislationaimed at exploring potential links between environmental exposure and breast

Two senators have introduced legislationaimed at exploring potential links between environmental exposure and breastcancer.

Sens. Harry Reid (D-Nev) and Lincoln Chafee (R-RI) want to give theNational Institute of Environmental Health Sciences (NIEHS) $30 million for thatpurpose. The Institute would use the money to fund eight research centers aroundthe country. 

The Breast Cancer and Environmental Research Act has beenintroduced into the House by Reps. Nita Lowey (D-NY) and Sue Myrick (R-NC). Inan appearance before a Senate appropriations subcommittee in May, NationalCancer Institute Director Richard Klausner said breast cancer deaths per 100,000women have increased from 83 in 1973 to 118 in 1998. Incidence rates areincreasing by about 1% a year for white women and remain unchanged forAfrican-American women. 

Women have a 1-in-8 lifetime risk of contracting breastcancer, and half of the incidence can be explained by currently known riskfactors, such as gene mutations. 

Dr. Klausner did not mention environmentalcauses as potentially contributing to the other half of incidence. Sen. Reid hasexpressed concern about the development of cancer in former nuclear weaponsworkers in Nevada. The NIEHS has considerable experience looking for linksbetween cancer and industrial environments and processes. 

At about the time Sen.Reid was introducing his bill, the NIEHS was releasing a report on a study in1,400 women in the northeast that showed no link between breast cancer and theindustrial chemicals DDT and PCB.

Articles in this issue

Clinical Radiation Oncology
Gemcitabine Active in Patients With Metastatic Breast Cancer
Docetaxel/Carboplatin Combination Produces Impressive Response in Ovarian Cancer Patients
Irinotecan in Lung and Other Malignancies
Excessive Paperwork Detracts From Patient Care, Professional Mentoring, and Research
Once-Yearly Leuprolide for Advanced Prostate Cancer Available
Older Breast Cancer Patients Benefit From Weekly Administration of Paclitaxel
Environmental Links to Breast Cancer
Bush Administration Considering Physician Ratings
Doxorubicin/Paclitaxel Combination Does Not Expose Breast Cancer Patients to Excessive Cardiac Risk
Atrasentan Prolongs Time to Progression in Prostate Cancer Patients
New Clinical Trial to Investigate Treatment Options After Tamoxifen
Prostate Cancer and Spinal Cord Compression
FDA Grants Priority Review to Capecitabine Plus Docetaxel for Breast Cancer
Current Status of Thalidomide in the Treatment of Cancer
Recent Videos
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Related Content
Advertisement

Trastuzumab rezetecan may represent a promising practice-changing therapeutic in this breast cancer population based on data from HORIZON-Breast01.

PFS Benefit Occurs With Trastuzumab Rezetecan in HER2+ Breast Cancer

Jason M. Broderick
October 19th 2025
Article

Trastuzumab rezetecan may represent a promising practice-changing therapeutic in this breast cancer population based on data from HORIZON-Breast01.


Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 8th 2025
Podcast

Up-front risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.


Data from OptiTROP-Breast02 support sac-TMT as a new treatment option for those with hormone receptor–positive, HER2-negative breast cancer.

Sacituzumab Tirumotecan Prolongs PFS Vs Chemo in Pretreated Breast Cancer

Andrea Eleazar, MHS
October 19th 2025
Article

Data from OptiTROP-Breast02 support sac-TMT as a new treatment option for those with hormone receptor–positive, HER2-negative breast cancer.


Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.


PAM Inhibition Adds Value in HR+/HER2- PIK3CA Wild Type Advanced Breast Cancer

PAM Inhibition Adds Value in HR+/HER2- PIK3CA Wild Type Advanced Breast Cancer

Kristie L. Kahl
October 19th 2025
Article

Gedatolisib enhanced PFS in advanced breast cancer, showcasing significant benefits when combined with fulvestrant and palbociclib.


T-DXd followed by THP is more effective and less toxic than dose-dense doxorubicin and cyclophosphamide then THP in this breast cancer population.

T-DXd-Based Neoadjuvant Therapy Improves pCR in High-Risk, HER2+ Breast Cancer

Chris Ryan
October 18th 2025
Article

T-DXd followed by THP is more effective and less toxic than dose-dense doxorubicin and cyclophosphamide then THP in this breast cancer population.

Related Content
Advertisement

Trastuzumab rezetecan may represent a promising practice-changing therapeutic in this breast cancer population based on data from HORIZON-Breast01.

PFS Benefit Occurs With Trastuzumab Rezetecan in HER2+ Breast Cancer

Jason M. Broderick
October 19th 2025
Article

Trastuzumab rezetecan may represent a promising practice-changing therapeutic in this breast cancer population based on data from HORIZON-Breast01.


Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 8th 2025
Podcast

Up-front risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.


Data from OptiTROP-Breast02 support sac-TMT as a new treatment option for those with hormone receptor–positive, HER2-negative breast cancer.

Sacituzumab Tirumotecan Prolongs PFS Vs Chemo in Pretreated Breast Cancer

Andrea Eleazar, MHS
October 19th 2025
Article

Data from OptiTROP-Breast02 support sac-TMT as a new treatment option for those with hormone receptor–positive, HER2-negative breast cancer.


Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.


PAM Inhibition Adds Value in HR+/HER2- PIK3CA Wild Type Advanced Breast Cancer

PAM Inhibition Adds Value in HR+/HER2- PIK3CA Wild Type Advanced Breast Cancer

Kristie L. Kahl
October 19th 2025
Article

Gedatolisib enhanced PFS in advanced breast cancer, showcasing significant benefits when combined with fulvestrant and palbociclib.


T-DXd followed by THP is more effective and less toxic than dose-dense doxorubicin and cyclophosphamide then THP in this breast cancer population.

T-DXd-Based Neoadjuvant Therapy Improves pCR in High-Risk, HER2+ Breast Cancer

Chris Ryan
October 18th 2025
Article

T-DXd followed by THP is more effective and less toxic than dose-dense doxorubicin and cyclophosphamide then THP in this breast cancer population.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.